Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2017

View Archived Issues

AntriaBio selects lead oral plasma kallikrein inhibitor candidates

InMed reports preclinical results in development of INM-405 for pain

OncBioMune Pharmaceuticals preparing clinical testing of OvcaVax

Lilly and CureVac enter global immune-oncology collaboration to develop mRNA cancer vaccines

Synspira commences phase Ia study of lead candidate for cystic fibrosis

Novartis starts phase I study of NMDA receptor NAM triggering milestone payment to Cadent

NexImmune, The Leukemia & Lymphoma Society to develop immunotherapy for AML

AST-2818 demonstrates antitumoral activity against EGFR T790M mutant NSCLC

Johnson & Johnson reviews highlights of third quarter 2017

Herpes vaccine HSV-529 safe and immunogenic in phase I trial

FDA gives fast track status to Radius Health's elacestrant

AbbVie and Harpoon Therapeutics enter immuno-oncology research collaboration

Mitsubishi Tanabe Pharma's acquisition of NeuroDerm complete

EMA grants orphan drug designation to Conatus' IDN-7314 for primary sclerosing cholangitis

Otsuka submits NDA for nalmefene in Japan

FDA advisory committee recommends approval of once-weekly semaglutide for type 2 diabetes

First-in-human phase I results presented for JNJ-64041757 immunotherapy in lung cancer

Astellas announces a new collaborative research agreement with TB Alliance

FDA approves CAR T therapy Yescarta for adults with relapsed or refractory large B-cell lymphoma

Sage Therapeutics describes novel NMDA receptor modulators

New glucosylceramidase activators identified at Lysosomal Therapeutics

FDA grants priority review to sNDA for Lynparza

AstraZeneca synthesizes novel serine-protein kinase ATM inhibitors

FluGen receives a grant from DOD to test universal flu vaccine against mismatched strains

University of Texas, Immune Sensor divulge new cyclic GMP-AMP synthase inhibitors

Loxo Oncology reports results from committee assessment of larotrectinib dataset

Protalix Biotherapeutics licenses PRX-102 to Chiesi outside U.S.

Vir Biotechnology collaborates with Alnylam and Visterra to develop programs for infectious diseases

Phase II luminespib study in non-small cell lung cancer meets primary endpoint

CEBPA gene novel mutation found to cause congenital lipodystrophy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...